| Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 BS Sheena, L Hiebert, H Han, H Ippolito, M Abbasi-Kangevari, ... The lancet Gastroenterology & hepatology 7 (9), 796-829, 2022 | 518 | 2022 |
| Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial M Malek, A Ashraf-Ganjouei, K Moradi, S Bagheri, MR Mohammadi, ... Clinical Neuropharmacology 43 (2), 39-45, 2020 | 36 | 2020 |
| The association between systemic inflammation and cognitive performance in healthy adults A Ashraf-Ganjouei, K Moradi, S Bagheri, MH Aarabi Journal of neuroimmunology 345, 577272, 2020 | 29 | 2020 |
| Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double‐blind, placebo … F Ghazizadeh‐Hashemi, S Bagheri, A Ashraf‐Ganjouei, K Moradi, ... Psychiatry and Clinical Neurosciences 75 (8), 250-255, 2021 | 28 | 2021 |
| The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways K Moradi, A Ashraf-Ganjouei, H Tavolinejad, S Bagheri, S Akhondzadeh Progress in Neuro-Psychopharmacology and Biological Psychiatry 106, 110091, 2021 | 28 | 2021 |
| Resveratrol adjunct therapy for negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial A Samaei, K Moradi, S Bagheri, A Ashraf-Ganjouei, R Alikhani, ... International Journal of Neuropsychopharmacology 23 (12), 775-782, 2020 | 25 | 2020 |
| Differences in the 2020 ESC versus 2015 ESC and 2014 ACC/AHA guidelines on the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation M Keykhaei, H Ashraf, S Rashedi, H Farrokhpour, B Heidari, S Zokaei, ... Current Atherosclerosis Reports 23, 1-11, 2021 | 23 | 2021 |
| Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: a randomized, double-blinded, placebo-controlled trial A Salehi, P Namaei, F TaghaviZanjani, S Bagheri, K Moradi, ... Psychiatry Research 316, 114737, 2022 | 20 | 2022 |
| Melatonin improves learning and memory of mice with chronic social isolation stress via an interaction between microglia polarization and BDNF/TrkB/CREB signaling pathway S Bagheri, K Moradi, E Ehghaghi, A Badripour, M Keykhaei, ... European Journal of Pharmacology 908, 174358, 2021 | 20 | 2021 |
| Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an … K Moradi, M Golbakhsh, F Haghighi, K Afshari, R Nikbakhsh, ... International Immunopharmacology 86, 106743, 2020 | 19 | 2020 |
| Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial? A Ayatollahi, S Bagheri, A Ashraf-Ganjouei, K Moradi, MR Mohammadi, ... Clinical neuropharmacology 43 (5), 139-145, 2020 | 19 | 2020 |
| Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial S Dehbozorghi, S Bagheri, K Moradi, K Shokraee, MR Mohammadi, ... Psychiatry and Clinical Neurosciences 73 (11), 690-696, 2019 | 14 | 2019 |
| Risk factors of tuberculosis treatment failure in South-East of Iran HA Adineh, B Motametdi, M Veisi, S Bagheri Journal of Gorgan University of Medical Sciences 16 (2), 50-56, 2014 | 13 | 2014 |
| Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial M Rafeiy-Torghabeh, A Ashraf-Ganjouei, K Moradi, S Bagheri, ... European child & adolescent psychiatry 30, 799-807, 2021 | 11 | 2021 |
| The first comprehensive cohort of the Duchenne muscular dystrophy in Iranian population: mutation spectrum of 314 patients and identifying two novel nonsense mutations G Zamani, A Hosseini Bereshneh, R Azizi Malamiri, S Bagheri, K Moradi, ... Journal of Molecular Neuroscience 70, 1565-1573, 2020 | 9 | 2020 |
| Evidence for anti-inflammatory effects of adalimumab in treatment of patients with major depressive disorder: A pilot, randomized, controlled trial F Abbasian, S Bagheri, K Moradi, M Keykhaei, A Etemadi, M Shalbafan, ... Clinical Neuropharmacology 45 (5), 128-134, 2022 | 5 | 2022 |
| Therapeutic application of saffron for improvement of women’s health: a review of literature S Bagheri, L Kashani Journal of Iranian Medical Council 4 (3), 115-124, 2021 | 5 | 2021 |
| Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial P Ebrahimi, H Seyedmirzaei, K Moradi, S Bagheri, M Moeini, ... International clinical psychopharmacology 38 (2), 89-95, 2023 | 4 | 2023 |
| Population attributable fraction estimates of cardiovascular diseases in different blood pressure levels in a large-scale cross-sectional study: a focus on prevention … M Keykhaei, N Rezaei, S Roshani, F Montazeri, M Nasserinejad, ... Blood Pressure Monitoring 28 (1), 1-10, 2023 | 3 | 2023 |
| Quality of Life in Patients with Cerebral Venous Sinus Thrombosis: A Study on Physical, Psychological, and Social Status of Patients in Long-term D Kajbaf, K Moradi, H Shamshiri, S Bagheri, R Rikhtegar, A Ghorbani, ... Archives of Iranian Medicine 24 (1), 15-21, 2021 | 2 | 2021 |
Shahin AkhondzadehPsychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Iran在 neda.net 的电子邮件经过验证
